Host-directed approaches to target granuloma pathways for treatment shortening in tuberculosis

This $7,352,643 federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports efforts by The Global Alliance For TB Drug Development Inc. (TB Alliance) to accelerate the development of new tuberculosis (TB) drugs and treatment regimens.

The grant, awarded on September 30, 2024 with a completion date of September 29, 2028, will fund TB Alliance's research on innovative, host-directed approaches to target granuloma pathways for shortened TB treatment. This includes investigating a host-directed proteolysis-targeting chimera (PROTAC) approach to target intracellular Mycobacterium tuberculosis, as well as evaluating the safety and efficacy of novel TB drug candidates and treatment regimens through clinical development and regulatory approval processes. The award builds on TB Alliance's existing federal contracts and grants supporting its mission to address significant TB health challenges for both civilian and military populations worldwide.